TB and HIV in children - advances in prevention and management

Paediatric Respiratory Reviews

Volumn 12, Issue 1, 2011, Pages 39-45

  Marais, B J ^a   Rabie, H ^a   Cotton, M F ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Children; HIV; TB

Indexed keywords

ABACAVIR; BCG VACCINE; EFAVIRENZ; ISONIAZID; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; STAVUDINE; ZIDOVUDINE;

BACTERIAL TRANSMISSION; BCG VACCINATION; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL TRIAL; CONGENITAL INFECTION; DIAGNOSTIC ACCURACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIDEMIC; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOCOMPROMISED PATIENT; INCIDENCE; LATENT TUBERCULOSIS; LIVER TOXICITY; LUNG TUBERCULOSIS; MILIARY TUBERCULOSIS; MIXED INFECTION; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; PATIENT COMPLIANCE; PERINATAL INFECTION; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; REINFECTION; REVIEW; SCREENING; SPUTUM CULTURE; SPUTUM SMEAR; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNSPECIFIED SIDE EFFECT; VERTICAL TRANSMISSION; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TUBERCULOSIS;

EID: 78650245719     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2010.09.002     Document Type: Review

References (84)

1. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009. WHO/STM/TB/2009.411. Geneva: World Health Organization, 2009.
2. Corbett E.L., Marston B., Churchyard G.J., De Cock K.M. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006, 367:926-937.
3. Heijnders M., van der Meij S. The fight against stigma: an overview of stigma-reduction strategies and interventions. Psychol Health Med 2006, 11:353-363.
4. Marais B.J., Schaaf H.S. Childhood Tuberculosis: an emerging and previously neglected problem. Infect Dis Clin N Am 2009, 24:727-749.
5. Marais B.J., Hesseling A.C., Gie R.P., Schaaf H.S., Beyers N. The burden of childhood tuberculosis and the accuracy of community-based surveillance data. Int J Tuberc Lung Dis 2006, 10:259-263.
6. Marais B.J., Obihara C.C., Warren R.M., et al. The burden of childhood tuberculosis: a public health perspective. Int J Tuberc Lung dis 2005, 9:1305-1313.
7. Marais B.J., Gie R.P., Schaaf H.S., et al. Childhood pulmonary tuberculosis: Old wisdom and new challenges. Am J Resp Crit Care Med 2006, 173:1078-1090.
8. Chintu C., Mudenda V., Lucas S., et al. Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet 2002, 360:985-990.
9. Harries A.D., Hargreaves N.J., Graham S.M., et al. Childhood tuberculosis in Malawi: nationwide case-finding and treatment outcomes. Int J Tuberc Lung Dis 2002, 6:424-431.
10. McNally L.M., Jeena P.M., Gajee K., et al. Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study. Lancet 2007, 369:1440-1451.
11. Marais B.J., Cotton M., Graham S.M., Beyers N. Diagnosis and management challenges of childhood TB in the era of HIV. Jnl Infect Dis 2007, 196(Suppl 1):S76-S85.
12. Lawn S.D., Bekker L.G., Middelkoop K., Myer L., Wood R. Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis 2006, 42:1040-1047.
13. Egwaga S.M. The impact of HIV on transmission of tuberculosis in Tanzania. Tuberculosis 2003, 83:66-67.
14. Kenyon T.A., Creek T., Laserson K., et al. Risk factors for transmission of Mycobacterium tuberculosis from HIV-infected tuberculosis patients, Botswana. Int J Tuberc Lung Dis 2002, 6:843-850.
15. Cotton M.F., Schaaf H.S., Lottering G., Wever H.L., Coetzee J., Nachman S. Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting. Int J Tuberc Lung Dis 2008, 12:225-227.
16. Marais B.J., Gie R.P., Schaaf H.S., et al. The natural history of childhood intra-thoracic tuberculosis - A critical review of the pre-chemotherapy literature. Int J Tuberc L Dis 2004, 8:392-402.
17. Elenga N., Kouakoussui K.A., Bonard D., Fassinou P., Anaky M.F., Wemin M.L., et al. Diagnosed tuberculosis during the follow-up of a cohort of human immunodeficiency virus-infected children in Abidjan, Cote d'Ivoire: ANRS 1278 study. Pediatr Infect Dis J 2005, 24:1077-1082.
18. Hesseling A.C., Cotton M.F., Jennings T., et al. High incidence of tuberculosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies. Clin Infect Dis 2009, 48:108-114.
19. Walters E., Cotton M.F., Rabie H., et al. Clinical presentation and outcome of TB in HIV-infected children on HAART. BMC Pediatrics 2008, 8:1.
20. World Health Organization. WHO three I's meeting. Report of a joint WHO HIV/AIDS and TB Department Meeting, 2008. WHO, Geneva. 2008.
21. Ayles H., Schaap A., Nota A., et al. Prevalence of tuberculosis, HIV and respiratory symptoms in two Zambian communities: implications for tuberculosis control in the era of HIV. PLoS ONE 2009, 4:e5602.
22. Wood R., Middelkoop K., Myer L., et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 2007, 175:87-93.
23. Corbett E.L., Bandason T., Cheung Y.B., et al. Epidemiology of Tuberculosis in a High HIV Prevalence Population Provided with Enhanced Diagnosis of Symptomatic Disease. PLoS Med 2007, 4:e22.
24. Corbett E.L., Bandason T., Cheung Y.B., et al. Prevalent infectious tuberculosis in Harare, Zimbabwe: burden, risk factors and implications for control. Int J Tuberc Lung Dis 2009, 13:1231-1237.
25. Shah S., Demissie M., Lambert L., et al. Intensified tuberculosis case finding among HIV-Infected persons from a voluntary counseling and testing center in Addis Ababa, Ethiopia. J Acquir Immune Defic Syndr 2009, 50:537-545.
26. Cain K.P., McCarthy K.D., Heilig C.M., et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 2010, 362:707-716.
27. Ghandi N.R., Moll A., Sturm A.W., et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area in South Africa. Lancet 2006, 368:1575-1580.
28. Bock N.N., Jensen P.A., Miller B., Nardell E. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect. Dis 2007, 196(Suppl 1):S108-S113.
29. World Health Organization. WHO policy on TB infection control in health-care facilities, congregate settings and households. WHO/HTM/TB/2009.419. 2009.
30. Escombe A.R., Oeser C.C., Gilman R.H., et al. Natural ventilation for the prevention of airborne contagion. PLoS Med 2007, 4:e68.
31. Escombe A.R., Moore D.A., Gilman R.H., Navincopa M., Ticona E., Mitchell B., et al. Upper-room ultraviolet light and negative air ionization to prevent tuberculosis transmission. PLoS Med 2009, 6:e43.
32. Marais B.J., Ayles H., Graham S.M., Godfrey-Faussett P. Screening and preventive therapy for tuberculosis. Chest Clin N Am 2009, 30:827-846.
33. World Health Organization. Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. WHO, Geneva, Switzerland. WHO/HTM/TB/2006.371.
34. Kruk A., Gie R.P., Schaaf H.S., Beyers N., Marais B.J. Symptom-based screening of child tuberculosis contacts: improved feasibility in resource-limited settings. Pediatrics 2008, 121:e1646-1652.
35. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004;(1):CD000171.
36. Marais B.J., van Zyl S., Schaaf H.S., et al. Adherence to isoniazid preventive chemotherapy, a prospective community based study. Arch Dis Child 2006, 91:762-765.
37. Van Zyl S., Marais B.J., Hesseling A.C., et al. Adherence to anti-tuberculosis chemoprophylaxis and treatment in children. Int J Tuberc Lung Dis 2006, 10:13-18.
38. Diero, L., Carter, E. J., Siika, A., et al. The experience and outcomes of isoniazid preventive therapy in an HIV treatment program in Western Kenya. International Conference on AIDS 2008 Aug 13-18;17 Abstract No.MoAb0306.2008.
39. Zar H.J., Cotton M.F., Strauss S., et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomized controlled trial. BMJ 2007, 334:136. 10.1136/bmj.3900.486400.55.
40. Madhi SA, McSherry G, Violari A, et al. Lack of Efficacy of Primary Isoniazid (INH) Prophylaxis in Reducing Tuberculosis (TB) Free Survival in HIV-infected (HIV+) African Children. In: Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC: IDSA /ASM; 2008.
41. Fine PE, Carneiro IAM, Milstien JB, Clements CJ. Issues relating to the use of BCG in immunization programmes. A discussion document. Department of vaccines and biologicals. WHO Geneva. Switzerland 1999: 1-33.
42. Trunz B.B., Fine P., Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006, 367:1173-1180.
43. Hesseling A.C., Johnson L.F., Jaspan H., et al. Disseminated bacilli Calmette-Guerin disease in HIV-infected South African infants. Bull World Health Organ 2009, 87:505-511.
44. Zhou D., Shen Y., Chalifoux L., et al. Mycobaterium bovis Bacille Calmette-Geurin enhances pathogenicity of Simian Immunodeficieny Virus infection and accelerates progression to AIDS in macaques: a role of persistent T cell activation in AIDS pathogenesis. J Immunol 1999, 162:2204-2216.
45. Hesseling A.C., Marais B.J., Gie R.P., et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2006, 10.1016/j.vaccine. 2006.07.020.
46. Global Advisory Committee on vaccine safety. Revised BCG vaccination guidelines for infants at risk for HIV infection. 25th May 2007. Wkly Epidemiol Rec 2007; 82: 181-196.
47. Hesseling A.C., Cotton M.F., Fordham von Reyn C., Graham S.M., Gie R.P., Hussey G.D. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis 2008, 12:1376-1379.
48. Badri M., Wilson D., Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002, 359:2059-2064.
49. Miranda A., Morgan M., Jamal L., et al. Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS ONE 2007, 2:e826.
50. Lawn S.D., Badri M., Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005, 19:2109-2116.
51. Lawn S.D., Myer L., Bekker L.G., Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006, 20:1605-1612.
52. Moore D., Liechty C., Ekwaru P., et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 2007, 21:713-719.
53. Walensky R.P., Wolf L.L., Wood R., et al. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2009, 151:157-166.
54. Violari A., Cotton M.F., Gibb D.M., Babiker A.G., Steyn J., Madhi S.A., Jean-Philippe P., McIntyre J.A. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008, 359:2233-2244. CHER Study Team.
55. http://www.who.int/hiv/pub/paediatric/art_meeting_april2008/en/index.html.
56. Golub J.E., Saraceni V., Cavalcante S.C., et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007, 21:1441-1448.
57. Golub J.E., Pronyk P., Mohapi L., et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009, 23:631-636.
58. Marais B.J., Pai M. New Approaches and emerging technologies in the diagnosis of childhood tuberculosis. Paediatr Respir Rev 2007, 8:124-133.
59. Marais B.J., Hesseling A.C., Gie R.P., Schaaf H.S., Enarson D.A., Beyers N. Bacteriologic confirmation may be achieved in the majority of children with intra-thoracic tuberculosis, in highly endemic settings. Clin Infect Dis 2006, 42:e69-71.
60. Franchi L.M., Cama R.I., Gilman R.H., Montenegro-James S., Sheen P. Detection of Mycobacterium tuberculosis in nasopharyngeal aspirate samples in children. Lancet 1998, 352:1681-1682.
61. Zar H.J., Hanslo D., Apolles P., Swingler G., Hussey G. Induced sputum versus gastric lavage for microbiological confirmation confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet 2005, 365:130-134.
62. Vargas D., Garcia L., Gilman R.H., et al. Diagnosis of sputum-scarce HIV-associated pulmonary tuberculosis in Lima, Peru. Lancet 2005, 365:150-152.
63. Hesseling A.C., Schaaf H.S., Gie R.P., Starke J.R., Beyers N. A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis. Int J Lung Dis 2002, 6:1038-1045.
64. Marais B.J., Obihara C.C., Gie R.P., et al. The prevalence of symptoms associated with pulmonary tuberculosis in randomly selected children from a high-burden community. Arch Dis Child 2005, 90:1166-1170.
65. Marais B.J., Gie R.P., Obihara C.C., Hesseling A.C., Schaaf H.S., Beyers N. Well-defined symptoms are of value in the diagnosis of childhood pulmonary tuberculosis. Arch Dis Child 2005, 90:1162-1165.
66. Marais B.J., Gie R.P., Hesseling A.C., et al. A refined symptom-based approach to diagnose pulmonary tuberculosis in children. Pediatrics 2006, 118:e1350-e1359.
67. Schaaf H.S., Krook S., Hollemans D.W., Warren R.M., Donald P.R., Hesseling A.C. Recurrent culture-confirmed tuberculosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2005, 24:685-691.
68. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. November 30, 2009. http://www.who.int/hiv/pub/arv/advice/en/index.html.
69. Gerstoft J., Kirk O., Obel N., Pedersen C., Mathiesen L., Nielsen H., et al. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS 2003, 17(14):2045-2052.
70. Ndembi N., Kaleebu P., Goodall R.L., et al. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomised comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. J Infect Dis 2010, 201:106-113.
71. Ren Y., Nuttall J.J., Eley B.S., et al. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2009, 50:439-443.
72. Prasitsuebsai W, Cressey TR, Capparelli E, et al. Pharmacokinetics of Nevirapine when Co-administered with Rifampin in HIV-Infected Thai Children with Tuberculosis. In: Congress of Retrovirology and Opportunistic Infection. Montreal, Canada; 2009, abstract 908.
73. Ren Y., Nuttall J.J., Egbers C., et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2008, 47:566-569.
74. McIlleron H, Ren Y, Nuttall J et al. Double- dose Lopinavir/Ritonovor Provides insufficient Lopinavir Exposure in children receiving tifampicin based Anti-Tb treatment. Conference of Retrovirus and Opportunistic Infections 2009 Abstract 98.
75. Narita M., Ashkin D., Hollender E.S., Pitchnik A.E. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Resp Crit Care Med 1998, 158:157-161.
76. Breen R.A., Smith C.J., Cropley I., Johnson M.A., Lipman M.C. Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy?. AIDS 2005, 19:1201-1206.
77. Meintjes G., Lawn S.D., Scano F., et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008, 8:516-523.
78. Puthanakit T., Oberdorfer P.M., Akarathum N., Wannarit P., Sirisanthana T., Sirisanthana V. Immune Reconstitution Syndrome After Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Thai Children. Pediatr Infect Dis J 2006, 25:53-58.
79. Hesseling A.C., Rabie H., Marais B.J., et al. Bacille Calmette-Guerin (BCG) vaccine-induced complications and HIV infection in children. Clin Inf Dis 2006, 42:548-558.
80. Rabie H, Violari A, Madhi S et al. Complications of BCG Vaccination in HIV-infected and -uninfected Children:CHER Study. 15th Conference On Retroviruses and Opportunistic Infections (CROI). Boston, Mass February 3-6, 2008.
81. Ahmed Y., Mwaba P., Chintu C., et al. A study of maternal mortality at University Teaching Hospital, Lusaka, Zambia: the emergence of tuberculosis as a major non-obstetric cause of maternal death. Int J Tuberc Lung Dis 1999, 3:675-680.
82. Khan M., Pillay, Moodley J.M., Connolly C.A. Maternal mortality associated with tuberculosis-HIV-1 Co-infection in Durban, South Africa. AIDS 2001, 15:1857-1863.
83. Pillay T., Khan M., Moodley J., et al. The increasing burden of TB in pregnant women, newborns and infants under 6 months of age in Durban, KwaZulu-Natal. S Afr Med J 2001, 91:983-987.
84. Marais B.J., Gupta A., Starke J.R., El-Sony A. Tuberculosis in women and children. Lancet 2010, 375:2057-2059.